Compare Amylx Pharmaceuticals Inc (AMLX) vs Atmos Energy Corporation (ATO) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amylx Pharmaceuticals Inc vs Atmos Energy Corporation — how do they compare? Amylx Pharmaceuticals Inc trades at $17.77 (market cap $1.98B), while Atmos Energy Corporation trades at $176.2 (market cap $29.41B). The key difference: Atmos Energy Corporation is far larger — about 14.9× Amylx Pharmaceuticals Inc's market cap, and Atmos Energy Corporation pays a 2.27% dividend while Amylx Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMLX | ATO | |
|---|---|---|
Market Cap | $1.98B | $29.41B |
Sector | Health | Utilities |
52-Week High | $18.70 | $192.25 |
52-Week Low | $7.64 | $154.10 |
Enterprise Value | $1.70B | $38.91B |
Dividend Yield | — | 2.27% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMLX trades at $17.77, down 3.32% today, with a bullish technical signal from moving averages and strong analyst support. The company is in a pivotal phase with key Phase 3 data for avexitide expected in Q3 2026, targeting a potential 2027 launch. Financially, it shows significant losses with negative ROE and ROA, but cash flow from financing activities provides runway. Recent news highlights clinical progress and conference presentations, alongside ongoing class action settlement discussions.
The outlook hinges on successful clinical trial outcomes, particularly avexitide's Phase 3 readout, which could drive substantial upside toward the $30.50 consensus price target. However, high execution risk, persistent cash burn, and legal overhangs pose threats to near-term stability. Investor sentiment remains cautiously optimistic given the 90.9% buy rating from analysts, but the stock is speculative until profitability milestones are achieved.
Atmos Energy (ATO) trades at $176.2, up 0.85% today, with a neutral technical signal. The stock shows strong fundamentals with revenue growth to $4.70B in 2025 and a net income margin of 27.58%. Recent Q1 2026 earnings beat expectations, and the company maintains a solid dividend. Analyst consensus is a Buy with a $189.67 price target, though technical indicators suggest near-term consolidation around key support and resistance levels.
The outlook for ATO is positive due to steady earnings growth, customer expansion, and supportive regulatory changes. Risks include high capital expenditures and exposure to energy market volatility. Institutional sentiment is bullish, with no sell ratings, positioning the stock for potential upside if operational execution continues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amylx Pharmaceuticals Inc
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →About Atmos Energy Corporation
Atmos Energy is the largest publicly traded, fully regulated, pure-play natural gas utility in the United States, serving more than 3 million customers in Texas, Colorado, Kansas, Kentucky, Louisiana, Mississippi, Tennessee, and Virginia. About two thirds of its earnings come from Texas, where it distributes natural gas in northern Texas and owns an intrastate gas pipeline spanning several key shale gas formations and interconnected with five storage facilities.
Read more on ATO →
